INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027GlobeNewsWire · 3 days ago
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with UnipharGlobeNewsWire · 3 days ago
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™PRNewsWire · Oct 14, 2026
INmune Bio to Attend the 2026 Maxim Growth SummitGlobeNewsWire · Oct 6, 2026
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to BoardGlobeNewsWire · Sep 14, 2026
INmune Bio to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire · Sep 9, 2026INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.21 | -$0.05 | Beat |
| May 7, 2026 | -$0.25 | -$0.20 | Beat |
| Mar 30, 2026 | -$0.27 | -$0.18 | Beat |
| Oct 30, 2025 | -$0.31 | -$0.24 | Beat |
| Aug 7, 2025 | -$0.37 | -$1.05 | Miss |
| May 8, 2025 | -$0.43 | -$0.43 | Beat |